Logo

GSK Signs a Research Collaboration with Clover for the Evaluation of Coronavirus (COVID-19) Vaccine

Share this

GSK Signs a Research Collaboration with Clover for the Evaluation of Coronavirus (COVID-19) Vaccine

Shots:

  • GSK to provide pandemic adjuvant system to Clover to evaluate S-Trimer in preclinical studies while Clover has largest commercial-scale cGMP biomanufacturing capabilities in China involved in rapid scale-up and produce new coronavirus vaccine
  • The focus of the collaboration is to evaluate the combination of GSK’s pandemic adjuvant system with Clover’s S-Trimer as a vaccine candidate utilizing its own Timer-Tag technology to develop vaccines for corona virus
  • Trimer-Tag technology is a drug development platform involved in production of novel covalently-trimerized fusion proteins targeted to these previously undruggable pathways

Click here to read full press release/ article

Ref: GSK | Image: GSK


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions